Letter: Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World Evidence

Abstract

Get full access to this article

View all access options for this article.

References

Worm

, Simpson

, Thaçi

, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020; 156(2):131–143; doi: 10.1001/jamadermatol.2019.3617

Spekhorst

, Boesjes

, Loman

, et al. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: A large pragmatic daily practice study from the BioDay registry. Br J Dermatol. 2023; 189(3):327–335; doi: 10.1093/bjd/ljad159

Mastorino

, Borrelli

, Macagno

, et al. Therapeutic modulation of dupilumab in patients with severe Atopic Dermatitis®: Clinical effectiveness in real life. Dermatitis. 2024; 35(6):625–635; doi: 10.1089/derm.2024.0146

Chiricozzi

, Dal Bello

, Gori

, et al. Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: A real-world study. J Dermatolog Treat. 2023; 34(1):2235041; doi: 10.1080/09546634.2023.2235041

Patruno

, Potestio

, Fabbrocini

, et al. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis. Dermatol Ther. 2022; 35(12):e15933; doi: 10.1111/dth.15933